Mikhail Blagosklonny is a well-known scientist. He mostly centers his research on cancer and targeted cancer therapies that protect normal cells from damage.
According to Research Gate, Mikhail Blagosklonny studied at the First Pavlov State Medical University where he earned an M.D in internal medicine and Ph.D. in experimental science. In 2009, he was appointed to serve as professor of Oncology at the Roswell Park Cancer Institute. He has previously served as an associate professor at the New York College.
Mikhail Blagosklonny has done numerous research in the field of biology, especially molecular and cellular biology. He has been credited with research works in clinical investigations such as cell senescence and signal transduction. Moreover, he has expanded this studies from cancer to aging.
He has formulated theories on the role of Target of Rapamycin (TOR) signaling in relation to cancer and aging. TOR is a protein kinase that regulates the level of growth in the body cells. He predicts the use of rapamycin in preventing aging in humans. His research has tried to find out if the continuous development of the body that causes aging can be slowed down by using pharmacological drugs.
He argues that growth-promoting signaling is necessary during the early stages of life but might be harmful as one grows old. However, the use rapamycin can be used in slowing down cancer, aging, and age-related diseases such as diabetes, Alzheimer, and cardiovascular diseases like hypertension.
Nature revealed that Mikhal Blagosklonny is also a renowned author. He has written more than 250 articles, reviews, and publication of his works. He is the Editor-in-Chief of the cell cycle and Oncotarget.
He also serves as the editor to Aging, the second best-ranked journal in aging research in 2013. He is an associate editor of Cell Death and Differentiation, Cancer Research, Cancer Biology and Therapy, International journal of Cancer, and PLOS ONE.